Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

The origins of new drugs

Nature Biotechnology volume 23, pages 529–530 (2005)Cite this article

A Corrigendum to this article was published on 01 August 2005

To the editor:

There is some debate as to the relative contribution of publicly funded research (universities, government research institutes and academic medical centers), biotech companies and pharmaceutical companies to the discovery of new medicines. To gain a clearer understanding of the origin of newly marketed drugs, I have analyzed data from the US Food and Drug Administration (FDA, Rockville, MD, USA), US Securities and Exchange Commission (SEC, Washington, DC) and the US Patent and Trademark Office (PTO, Washington, DC) to determine the origin of most of the new molecular entities (NMEs) and new biological entities (NBEs) approved by the FDA from 1998 to 2003.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Cockburn, I. & Henderson, R. Public-Private Interaction and the Productivity of Pharmaceutical Research. National Bureau of Economic Research (NBER) Working Paper 6018 (NBER, Cambridge, MA, 1997).

    Book  Google Scholar 

  2. Powell, W.W., Korput, K.W. & Smith-Doerr, L. Administr. Sci. Quart. 41, 116–145 (1996).

    Article  Google Scholar 

  3. Murray, F. Res. Policy 31, 1389–1403 (2002).

    Article  Google Scholar 

  4. Henderson, R., Orsenigo, L. & Pisano, G.P. in Sources of Industrial Leadership, Studies of Seven Industries (eds. Mowery, D. & Nelson, R.) 267–311 (Cambridge University Press, Cambridge, UK, 1999).

    Book  Google Scholar 

  5. McKelvey, M. Evolutionary Innovations, the Business of Biotechnology (Oxford University Press, Oxford, 1996).

    Google Scholar 

  6. Zucker, L.G. & Darby, M.R. Proc. Natl. Acad. Sci. USA 93, 12709–12716 (1996).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Tokyo, RCAST, 4-6-1 Komaba, Meguro-ku, Tokyo, 153-8904, Japan

    Robert Kneller

Authors
  1. Robert Kneller
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kneller, R. The origins of new drugs. Nat Biotechnol 23, 529–530 (2005). https://doi.org/10.1038/nbt0505-529

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0505-529

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing